Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.

ABSTRACT:

Objective

The authors assessed the efficacy and safety of combination treatment with varenicline and sustained-release bupropion for smokers who, based on an assessment of initial smoking reduction prior to the quit date, were deemed unlikely to achieve abstinence using nicotine patch treatment.

Method

In a randomized, double-blind, parallel-group adaptive treatment trial, the authors identified 222 cigarette smokers who failed to show a reduction of more than 50% in smoking after 1 week of nicotine patch treatment. Smokers were randomly assigned to receive 12 weeks of varenicline plus bupropion or varenicline plus placebo. The primary outcome measure was continuous smoking abstinence at weeks 8-11 after the target quit date.

Results

Both treatments were well tolerate

SUBMITTER: Rose JE 

PROVIDER: S-EPMC4557205 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature